{"id":"ql1706","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"15-25%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"QL1706 works by binding to the PI3K/AKT pathway, which is involved in cell growth and survival. This binding inhibits the pathway, leading to reduced cancer cell growth and proliferation.","oneSentence":"QL1706 is a small molecule targeting the PI3K/AKT pathway to inhibit cancer cell growth.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:30:59.769Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer"},{"name":"Metastatic breast cancer"}]},"trialDetails":[{"nctId":"NCT07453394","phase":"PHASE1, PHASE2","title":"QLS5132 Combination Therapy in Advanced Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2026-04","conditions":"Gastric Cancer (GC), Non-small Cell Lung Cancer (NSCLC), Endometrial Cancer","enrollment":626},{"nctId":"NCT07452003","phase":"NA","title":"An Exploratory Study of QL1706 Plus Chemotherapy in Perioperative NSCLC","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2026-01-03","conditions":"Non-Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT07446387","phase":"PHASE2","title":"A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2026-02-01","conditions":"Metastatic Colorectal Cancer (CRC)","enrollment":70},{"nctId":"NCT06787183","phase":"PHASE2","title":"SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver Metastases","status":"RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-12-01","conditions":"Locally Advanced Rectal Cancer With Liver Metastases","enrollment":42},{"nctId":"NCT07342283","phase":"PHASE2","title":"QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"Affiliated Hospital of Nantong University","startDate":"2026-02-25","conditions":"Triple Negative Breast Cancer (TNBC)","enrollment":30},{"nctId":"NCT07432594","phase":"PHASE2","title":"Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-03-01","conditions":"High-grade Serous Ovarian Cancer (HGSOC), Fallopian Tube Cancers, Primary Peritoneal Cancer","enrollment":82},{"nctId":"NCT07416058","phase":"PHASE2","title":"PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Guangdong Association of Clinical Trials","startDate":"2026-01-31","conditions":"Lung Adenocarcinoma","enrollment":61},{"nctId":"NCT07413601","phase":"PHASE2","title":"Phase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinum Chemotherapy in the Treatment of Second-/Third-line Triple Negative Breast Cancer (TNBC)","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-02-10","conditions":"Triple Negative Breast Cancer Metastatic","enrollment":78},{"nctId":"NCT07407452","phase":"PHASE2","title":"Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2026-02-01","conditions":"Ovarian Cancers","enrollment":50},{"nctId":"NCT07400315","phase":"PHASE2","title":"First-line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma With Dual Immunotherapy Combined With Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-03-01","conditions":"Gastric or Gastroesophageal Junction Adenocarcinoma","enrollment":64},{"nctId":"NCT07396324","phase":"PHASE2","title":"Neoadjuvant Iparomlimab and Tuvonralimab (QL1706) in Patients With Hormone Receptor Positive, HER2-negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"RenJi Hospital","startDate":"2026-03","conditions":"Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer","enrollment":55},{"nctId":"NCT07389629","phase":"PHASE2","title":"Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-11-21","conditions":"Iparomlimab and Tuvonralimab, Clear Cell Renal Cell Carcinoma, Neoadjuvant Therapy","enrollment":25},{"nctId":"NCT07384416","phase":"PHASE2","title":"Single-Arm Trial of QL1706, Lenvatinib, and Nab-Paclitaxel for Advanced Refractory Penile Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-10","conditions":"Penile Cancer","enrollment":47},{"nctId":"NCT07383285","phase":"PHASE2","title":"CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2026-02-01","conditions":"Rectal Neoplasms Malignant","enrollment":106},{"nctId":"NCT07372079","phase":"PHASE2","title":"Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-04-05","conditions":"Breast Cancer, Neoadjuvant Therapy, Immune Checkpoint Inhibitors","enrollment":40},{"nctId":"NCT07369986","phase":"PHASE2","title":"Immunotherapy for Surgery Avoidance in Vulnerable dMMR Endometrial Cancer","status":"NOT_YET_RECRUITING","sponsor":"Women's Hospital School Of Medicine Zhejiang University","startDate":"2026-03-01","conditions":"Endometrial Cancer, Immunotherapy, Mismatch Repair Deficiency","enrollment":30},{"nctId":"NCT06951997","phase":"PHASE2","title":"QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-03-07","conditions":"Metastatic Pancreatic Cancer","enrollment":33},{"nctId":"NCT07328009","phase":"PHASE2","title":"A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-01-25","conditions":"Hepato Cellular Carcinoma (HCC)","enrollment":350},{"nctId":"NCT07353268","phase":"PHASE2","title":"Phase Ib/II Study of QL1706 + Fruquintinib + SCRT vs. Standard Third-Line Therapy in Unresectable Liver-Metastatic pMMR/MSS Colorectal Cancer: Safety, Tolerability, and Efficacy.","status":"NOT_YET_RECRUITING","sponsor":"Tao Zhang","startDate":"2026-01-21","conditions":"Colorectal Cancer","enrollment":76},{"nctId":"NCT07327788","phase":"PHASE2","title":"QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT","status":"RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2025-12-25","conditions":"Hepatecellular Carcinoma, RALOX-HAIC（Hepatic Arterial Infusion Chemotherapy With Raltitrexed and Oxaliplatin, Bevacizumab","enrollment":38},{"nctId":"NCT07330596","phase":"PHASE2","title":"QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC","status":"RECRUITING","sponsor":"Anhui Provincial Cancer Hospital","startDate":"2025-10-30","conditions":"NSCLC (Advanced Non-small Cell Lung Cancer)","enrollment":96},{"nctId":"NCT07229846","phase":"PHASE2","title":"A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation","status":"NOT_YET_RECRUITING","sponsor":"Yanqiao Zhang","startDate":"2026-02","conditions":"Colorectal Cancer","enrollment":30},{"nctId":"NCT06967103","phase":"PHASE2","title":"QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast Cancer","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2025-09-08","conditions":"Breast Cancer, HR+/HER2- Breast Cancer","enrollment":238},{"nctId":"NCT07315854","phase":"PHASE2","title":"Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer","status":"RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2025-11-04","conditions":"Gastric Cancer (GC), Gastroesophageal Junction Cancer, Advanced Gastric Cancer","enrollment":32},{"nctId":"NCT07110064","phase":"PHASE2","title":"QL1706+Lenvatinib+AG Regimen as First-line Treatment for Advanced Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"Du Juan","startDate":"2025-09-03","conditions":"Advance Pancreatic Cancer","enrollment":80},{"nctId":"NCT07315035","phase":"PHASE2","title":"QL1706-SOX vs SOX Alone as Neoadjuvant Therapy for Resectable Diffuse-Type Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-01-01","conditions":"Gastric Cancer Stage III","enrollment":74},{"nctId":"NCT06801665","phase":"PHASE2","title":"FMT+ QL1706+Bevacizumab+ XELOX as First-line Treatment for Advanced MSS-type Colon Cancer With Liver Metastasis","status":"RECRUITING","sponsor":"Hua Jiang","startDate":"2025-04-17","conditions":"Colon Cancer Liver Metastases","enrollment":30},{"nctId":"NCT07268131","phase":"NA","title":"TITAN-HCC: Neoadjuvant and Adjuvant QL1706 With TACE in Resectable Hepatocellular Carcinoma Beyond Milan Criteria","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-12-20","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":30},{"nctId":"NCT06686576","phase":"PHASE3","title":"A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2024-12-12","conditions":"Colon Cancer","enrollment":363},{"nctId":"NCT07291401","phase":"PHASE2","title":"Radiotherapy Plus CAPOX, and Iparomlimab and Tuvonralimab (QL1706) as Neoadjuvant Therapy for LARC","status":"NOT_YET_RECRUITING","sponsor":"Zhongnan Hospital","startDate":"2026-01-01","conditions":"Rectal Cancer Patients","enrollment":108},{"nctId":"NCT07291947","phase":"PHASE1, PHASE2","title":"PULSAR Combined With Immunotherapy and Chemotherapy","status":"RECRUITING","sponsor":"Wang Xin","startDate":"2025-11-04","conditions":"Cholangiocarcinoma","enrollment":60},{"nctId":"NCT07289997","phase":"PHASE2","title":"Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC)","status":"RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2025-09-28","conditions":"AFP Gastric or Gastroesophageal Junction Adenocarcinoma, PD-1/CTLA-4, AFPGC","enrollment":39},{"nctId":"NCT07286253","phase":"PHASE2","title":"QL1706 Plus Chemotherapy as Neoadjuvant Therapy for Locally Advanced Cervical Cancer: A Phase II Trial","status":"RECRUITING","sponsor":"Affiliated Cancer Hospital & Institute of Guangzhou Medical University","startDate":"2025-10-28","conditions":"Neoadjuvant Treatment for Locally Advanced Cervical Cancer","enrollment":50},{"nctId":"NCT07283991","phase":"PHASE2","title":"QL1706 Plus Chemotherapy for Borderline Resectable Esophageal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-12-30","conditions":"Esophageal Cancer","enrollment":24},{"nctId":"NCT07286240","phase":"PHASE2","title":"QL1706 Combined With Chemotherapy and Anlotinib for the Treatment of Recurrent Ovarian Cancer","status":"RECRUITING","sponsor":"Affiliated Cancer Hospital & Institute of Guangzhou Medical University","startDate":"2025-11-15","conditions":"Treatment of Recurrent Ovarian Cancer","enrollment":40},{"nctId":"NCT07286942","phase":"PHASE2","title":"Stereotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (QL1706) + Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Non-small-cell Lung Cancer in China (LUNG-Nanjing01): a Single-arm, Single-centre, Phase 2 Trial","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2025-12-18","conditions":"NSCLC, NSCLC (Non-small Cell Lung Cancer)","enrollment":24},{"nctId":"NCT07179900","phase":"PHASE2","title":"Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2025-12","conditions":"Hepatocellular Carcinoma","enrollment":60},{"nctId":"NCT07271602","phase":"PHASE2","title":"A Phase 2 Randomized, Controlled Trial of QL1706 Plus Chemotherapy and Quad Shot for Driver Gene-negative Advanced Non-small Cell Lung Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2026-01-30","conditions":"Non Small Cell Lung Cancer, Immunotherapy, Radiotherapy","enrollment":104},{"nctId":"NCT07272590","phase":"PHASE1, PHASE2","title":"Study of QLC5513 in Combination With Epalolimab Tovolimab (QL1706) ± Platinum in Patients With Advanced or Metastatic Malignant Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-12-30","conditions":"Metastatic Solid Tumors","enrollment":290},{"nctId":"NCT07232654","phase":"PHASE2","title":"Iparomlimab/Tuvonralimab Injection Plus CCRT in LACC","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-11-11","conditions":"LOCALLY ADVANCED CERVICAL CANCERS","enrollment":30},{"nctId":"NCT07256236","phase":"PHASE2","title":"SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-12-15","conditions":"Cervical Cancer","enrollment":89},{"nctId":"NCT07256782","phase":"PHASE1, PHASE2","title":"A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-10-24","conditions":"Advanced Solid Tumor","enrollment":444},{"nctId":"NCT07246317","phase":"PHASE2","title":"Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-12-15","conditions":"Breast Cancer","enrollment":188},{"nctId":"NCT07178171","phase":"PHASE1","title":"A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBC","status":"RECRUITING","sponsor":"Xijing Hospital","startDate":"2025-11-06","conditions":"TNBC, Triple Negative Breast Cancer","enrollment":30},{"nctId":"NCT06939855","phase":"PHASE2","title":"QL1706 in the Treatment of Advanced Bone and Soft Tissue Sarcoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-09-28","conditions":"Bone and Soft Tissue Tumors","enrollment":45},{"nctId":"NCT05690945","phase":"PHASE3","title":"A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2023-02-15","conditions":"Lung Cancer","enrollment":606},{"nctId":"NCT07180160","phase":"PHASE2","title":"Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer","status":"RECRUITING","sponsor":"Wenjin Yin","startDate":"2025-09-25","conditions":"Advanced Breast Cancer","enrollment":123},{"nctId":"NCT07229872","phase":"PHASE2","title":"A Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Fruquintinib in the Treatment of Immunodominant pMMR/MSS Metastatic Colorectal Cancer That Has Failed Second-line or Above Treatment","status":"NOT_YET_RECRUITING","sponsor":"Harbin Medical University","startDate":"2025-12","conditions":"Colorectal Cancer","enrollment":18},{"nctId":"NCT07205497","phase":"PHASE2","title":"QL1706 Plus Neoadjuvant Chemotherapy Followed by Type I Hysterectomy for Locally Advanced Cervical Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-03-28","conditions":"Neoadjuvant Immunotherapy, Locally Advanced Cervical Cancer","enrollment":54},{"nctId":"NCT07205185","phase":"PHASE2","title":"A Multicenter, Single-arm, Prospective Phase II Clinical Study of Epalrotokewali Combined With Eribulin, Anlotinib, and Radiotherapy for the Treatment of Patients With Advanced Soft Tissue Sarcoma.","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-10-01","conditions":"Soft Tissue Sarcoma (STS)","enrollment":46},{"nctId":"NCT07200947","phase":"PHASE2","title":"A Phase II Study of QL1706 and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Non-Small Cell Lung Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Zhijie Wang","startDate":"2025-12-01","conditions":"SMARCA4-Deficient Tumor, Locally Advanced or Metastatic Non-Small Cell Lung Cancer","enrollment":28},{"nctId":"NCT07197697","phase":"PHASE2","title":"A Phase II Exploratory Study of Iparomlimab and Tuvonralimab Combined With Chemotherapy in Neoadjuvant Treatment of HR+/HER2- Breast Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Anhui Provincial Cancer Hospital","startDate":"2025-10-10","conditions":"Breast Cancer","enrollment":30},{"nctId":"NCT07150247","phase":"PHASE2","title":"Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-06-01","conditions":"BRAF V600 Colorectal Cancer","enrollment":20},{"nctId":"NCT07187674","phase":"NA","title":"The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab and Tuvonralimab Combined With Olaparib and Paclitaxel","status":"NOT_YET_RECRUITING","sponsor":"Harbin Medical University","startDate":"2025-12-30","conditions":"Triple Negative Breast Cancer (TNBC)","enrollment":20},{"nctId":"NCT07186868","phase":"","title":"QL706 + Chemo ± Bevacizumab in Anti-PD-(L)1-Resistant R/M Cervical Cancer","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-10-15","conditions":"Recurrent Cervical Cancer, Metastatic Cervical Cancer","enrollment":25},{"nctId":"NCT07175636","phase":"PHASE2","title":"QL1706 With Short-Course Radiotherapy and Chemotherapy for MSS Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-09-20","conditions":"Locally Advanced Rectal Cancer (LARC), Mismatch Repair-Proficient (pMMR) Rectal Cancer, Non-metastatic Rectal Cancer","enrollment":66},{"nctId":"NCT07172217","phase":"PHASE2","title":"The Efficacy and Safety RC48 Plus QL1706 in Second-Line Treatment of HER2-Expressing Recurrent CC","status":"NOT_YET_RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2025-10-01","conditions":"Recurrent Cervical Cancer","enrollment":33},{"nctId":"NCT07156682","phase":"PHASE2","title":"QL1706 Plus XELOX as Neoadjuvant Therapy for MSS/pMMR Clinical Stage III Colon Cancer","status":"NOT_YET_RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2025-09-25","conditions":"Colon Cancer, MSS/pMMR, QL1706","enrollment":21},{"nctId":"NCT06313970","phase":"PHASE2","title":"First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-06-20","conditions":"Pancreatic Cancer","enrollment":58},{"nctId":"NCT07150377","phase":"PHASE2","title":"A Phase II Single-Arm Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Lenvatinib and TACE for Advanced Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"The Second Affiliated Hospital of Shandong First Medical University","startDate":"2025-08-24","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":41},{"nctId":"NCT07099274","phase":"PHASE2","title":"Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy for Unresectable Intermediate-to-Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-08-22","conditions":"HCC","enrollment":29},{"nctId":"NCT07117877","phase":"PHASE2","title":"Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-09-15","conditions":"Platinum Resistant Ovarian Cancer, Platinum Refractory Epithelial Ovarian Cancer, Ovarian Cancer (OvCa)","enrollment":33},{"nctId":"NCT07141186","phase":"PHASE2","title":"QL1706 in Patients With Recurrent and Metastatic Cervical Cancer Resistant to Prior PD-1/PD-L1 Antibody Therapy","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-10-01","conditions":"Cervical Cancer, Cervical Cancer Metastatic, Cervical Cancer Recurrent","enrollment":50},{"nctId":"NCT07138885","phase":"PHASE2","title":"A Phase II, Single-Arm, Prospective Trial on the Efficacy and Safety of QL1706 Combination Regimen as Second-Line Therapy for Targeted-Immunotherapy-Resistant Hepatocellular Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-08-01","conditions":"Hepatocellular Carcinoma (HCC), Second Line Treatment","enrollment":62},{"nctId":"NCT07135804","phase":"PHASE2","title":"Iparomlimab and Tuvonralimab Injection for Untreated Locally Advanced Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2025-09-01","conditions":"Locally Advanced Nasopharyngeal Squamous Cell Carcinoma","enrollment":45},{"nctId":"NCT07134413","phase":"PHASE2","title":"QL1706/Bevacizumab ± Chemotherapy in Post-ICI Non-Squamous NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Guangdong Association of Clinical Trials","startDate":"2025-08","conditions":"NSCLC","enrollment":77},{"nctId":"NCT07131345","phase":"PHASE1, PHASE2","title":"Study of Iparomlimab and Tuvonralimab Plus Chemotherapy in Malignant Mesothelioma","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Center, China","startDate":"2025-09-01","conditions":"Malignant Mesothelioma, Mesothelioma","enrollment":55},{"nctId":"NCT07131501","phase":"PHASE2","title":"A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-08-11","conditions":"Hepatocellular Carcinoma, Immunotherapy, Preoperative","enrollment":48},{"nctId":"NCT07128251","phase":"PHASE2","title":"A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)","status":"NOT_YET_RECRUITING","sponsor":"Anhui Provincial Hospital","startDate":"2025-08-20","conditions":"Hepatocellular Carcinoma (HCC), Immunotherapy, PD-1","enrollment":47},{"nctId":"NCT07070700","phase":"PHASE2","title":"Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahepatic Cholangiocarcinoma","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-08-20","conditions":"Intrahepatic Cholangiocarcinoma (Icc)","enrollment":56},{"nctId":"NCT07113964","phase":"PHASE2","title":"QL1706 With Olaparib for Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency (HRD)","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-08-30","conditions":"Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency","enrollment":79},{"nctId":"NCT07116577","phase":"PHASE2","title":"Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC","status":"NOT_YET_RECRUITING","sponsor":"Jinan Central Hospital","startDate":"2025-08-31","conditions":"mCRC","enrollment":37},{"nctId":"NCT07115550","phase":"NA","title":"A Single-center, Single-arm, Phase II Clinical Study of Iparomlimab and Tuvonralimab Injection Combined With Regorafenib in the Treatment of Advanced Second-line or Above Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Huai'an First People's Hospital","startDate":"2025-08-26","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":24},{"nctId":"NCT06897046","phase":"PHASE2","title":"Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-07-30","conditions":"Non-small Cell Lung Cancer (NSCLC), II-IIIB","enrollment":90},{"nctId":"NCT07091305","phase":"PHASE2","title":"A Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2025-07-01","conditions":"Limited-stage Small Cell Lung Cancer (LS-SCLC), Chemoradiotherapy, Induction Therapy","enrollment":28},{"nctId":"NCT07085234","phase":"PHASE2","title":"Iparomlimab/Tuvorlimab (QL1706) and Modified TPF Regimen for Induction Therapy in LANPC","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2025-07-30","conditions":"Locally Advanced Nasopharyngeal Carcinoma, Immunotherapy, Induction Therapy","enrollment":30},{"nctId":"NCT07083375","phase":"PHASE2","title":"A Phase II Study of QL1706 With Anti-angiogenesis Therapy and Chemotherapy in Extensive-stage Small Cell Lung Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Zhijie Wang","startDate":"2025-08-01","conditions":"Extensive Small Cell Lung Cancer","enrollment":56},{"nctId":"NCT07070713","phase":"PHASE2","title":"Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-07-30","conditions":"Metastatic Colorectal Cancer With Left-sided Primary Tumor, Immunotherapy","enrollment":44},{"nctId":"NCT07062055","phase":"PHASE2","title":"BRAVE Study: QL1706 + Bevacizumab + SBRT for BCLC-C HCC With PVTT or Oligometastases","status":"RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2025-07-25","conditions":"Hepatocellular Carcinoma, Portal Vein Tumor Thrombus, Oligometastases","enrollment":46},{"nctId":"NCT06892925","phase":"PHASE2","title":"QL1706 Combined With Lenvatinib and GEMOX as First - Line Treatment for Unresectable Biliary Tract Tumors","status":"RECRUITING","sponsor":"Eastern Hepatobiliary Surgery Hospital","startDate":"2025-06-14","conditions":"Biliary Tract Tumors","enrollment":59},{"nctId":"NCT07049185","phase":"PHASE2","title":"QL1706 Plus Celecoxib in Advanced Esophageal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2025-07-15","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":35},{"nctId":"NCT06893887","phase":"NA","title":"Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Nanjing Tianyinshan Hospital","startDate":"2025-05-22","conditions":"Hepatocellular Carcinoma(HCC)","enrollment":300},{"nctId":"NCT07046780","phase":"","title":"A Multicenter, Prospective, Non-Interventional Real-World Study of Iparomlimab and Tuvonralimab Injection (QL1706) in the Treatment of Locally Advanced or Metastatic Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"PENG YUAN","startDate":"2025-07-30","conditions":"Solid Tumor Cancer, Metastatic Solid Tumors, Locally Advanced","enrollment":90},{"nctId":"NCT07045805","phase":"PHASE2","title":"Phase II Study of QL1706 Combined With Paclitaxel and Bevacizumab for Second-Line Immune Rechallenge in Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2025-07-25","conditions":"Gastric Cancer (GC)","enrollment":66},{"nctId":"NCT07035808","phase":"PHASE2","title":"a Single Arm, Phase II Multicenter Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of Iparomlimab and Tuvonralima b and Chemotherapy ± Bevacizumab Induction Therapy Followed by Concurrent Chemoradiotherapy in Patients With Advanced Cervical Cancer .","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2025-07-01","conditions":"Cervical Cancer Stage IVA, Cervical Cancer Metastatic","enrollment":46},{"nctId":"NCT07026422","phase":"PHASE2","title":"Iparomlimab/Tuvonralimab Integrating With Total Neoadjuvant Therapy for pMMR/MSS Locally Advanced Rectal Cancer (IT-TNT)","status":"RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2025-05-30","conditions":"Rectal Malignant Neoplasms","enrollment":54},{"nctId":"NCT06766305","phase":"PHASE1, PHASE2","title":"QL1706 Combined With SOX Used in Theperioperative Treatment","status":"RECRUITING","sponsor":"Xiangdong Cheng","startDate":"2025-03-21","conditions":"Gastric Cancers, Esophagogastric Junction Cancers","enrollment":54},{"nctId":"NCT07025239","phase":"PHASE3","title":"QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-07","conditions":"Metastatic Colorectal Cancer","enrollment":430},{"nctId":"NCT06954116","phase":"PHASE2","title":"Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-01","conditions":"Resectable Hepatocellular Carcinoma With High Risk of Recurrence","enrollment":26},{"nctId":"NCT07009145","phase":"PHASE2","title":"QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC","status":"NOT_YET_RECRUITING","sponsor":"Qianfoshan Hospital","startDate":"2025-06-27","conditions":"Unresectable Colorectal Cancer, Metastatic Colorectal Cancer (CRC), MSI-H/dMMR Colorectal Cancer","enrollment":22},{"nctId":"NCT07005583","phase":"PHASE2","title":"Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-06-30","conditions":"Triple-Negative Breast Cancer (TNBC)","enrollment":46},{"nctId":"NCT07002346","phase":"PHASE3","title":"INVIGORATE: A Study of QL1706 and Bevacizumab in Advanced First-Line Ovarian Clear Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-06-01","conditions":"Ovarian Clear Cell Carcinoma","enrollment":226},{"nctId":"NCT06986057","phase":"PHASE2","title":"Iparomlimab and Tuvonralimab Combined With Platinum-Based Chemotherapy for Neoadjuvant Treatment of Cervical Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shandong Tumor Hospital","startDate":"2025-05-31","conditions":"Cervical Cancer, Neoadjuvant Therapy","enrollment":28},{"nctId":"NCT06749899","phase":"PHASE3","title":"QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.","status":"RECRUITING","sponsor":"Sun Yat-Sen University Cancer Center","startDate":"2025-05-04","conditions":"Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer","enrollment":580},{"nctId":"NCT06809530","phase":"PHASE1, PHASE2","title":"Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis","status":"RECRUITING","sponsor":"Guangzhou Medical University","startDate":"2025-03-17","conditions":"Leptomeningeal Metastasis, Pemetrexed, PD-1 Inhibitor","enrollment":34},{"nctId":"NCT06958484","phase":"PHASE2","title":"Iparomlimab and Tuvonralimab Injection (QL1706) Combined With Bevacizumab for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma (HCC) With High Risk of Recurrence","status":"NOT_YET_RECRUITING","sponsor":"The Affiliated Hospital of Xuzhou Medical University","startDate":"2025-05-01","conditions":"HCC - Hepatocellular Carcinoma, Adjuvant Treatment","enrollment":60},{"nctId":"NCT06941766","phase":"PHASE1, PHASE2","title":"Iparomlimab and Tuvonralimab (QL1706) for Intermediate Trophoblastic Tumors","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-04-15","conditions":"Intermediate Trophoblastic Tumor","enrollment":20},{"nctId":"NCT06949761","phase":"PHASE1, PHASE2","title":"A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of QLC1101 in Combination With Other Therapies in the Treatment of Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-06","conditions":"Solid Tumor","enrollment":240},{"nctId":"NCT06911684","phase":"PHASE2","title":"Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC.","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-04-30","conditions":"Rectal Cancer Patients","enrollment":88},{"nctId":"NCT06908382","phase":"PHASE2","title":"Neoadjuvant QL1706 Therapy for ESCC","status":"RECRUITING","sponsor":"Shandong Provincial Hospital","startDate":"2025-04-28","conditions":"Locally Advanced Resectable Esophageal Squamous Cell Carcinoma","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["bevacizumab","albumin-binding paclitaxel","Iparomlimab and Tuvonralimab Injection","Iparomlimab and Tuvonralimab，PSB205","PSB205"],"phase":"phase_3","status":"active","brandName":"QL1706","genericName":"QL1706","companyName":"Fujian Cancer Hospital","companyId":"fujian-cancer-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"QL1706 is a small molecule targeting the PI3K/AKT pathway to inhibit cancer cell growth. Used for Metastatic non-small cell lung cancer, Metastatic breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}